Immunocore Holdings plc - American Depositary Shares (IMCR)
32.51
+0.13 (0.40%)
NASDAQ · Last Trade: Feb 18th, 11:46 AM EST
Detailed Quote
Previous Close
32.38
Open
32.50
Bid
32.46
Ask
32.54
Day's Range
32.03 - 33.23
52 Week Range
23.15 - 40.71
Volume
213,793
Market Cap
1.43B
PE Ratio (TTM)
-57.04
EPS (TTM)
-0.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
494,748
Chart
About Immunocore Holdings plc - American Depositary Shares (IMCR)
Immunocore Holdings Plc is a biotechnology company that specializes in the development of innovative T cell receptor-based therapies to treat a range of diseases, including cancer and autoimmune conditions. The company focuses on harnessing the power of the immune system by creating treatments designed to engage T cells, which play a critical role in the body's defense against diseases. Through its proprietary technology platform, Immunocore aims to develop a new class of drugs that can effectively target and destroy diseased cells while minimizing impact on healthy tissues. The company's research and clinical efforts are driven by a commitment to advancing science and improving patient outcomes in areas of significant unmet medical need. Read More
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, November 10, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November.
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025.
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2025 Jefferies Global Healthcare Conference.
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in March.
